New research suggests that a common but controversial treatment for prostate cancer reduces long-term death rates without greatly boosting patients' risk of heart problems.
February 2008
The American Society of Hematology (ASH) held its 49th AnnualMeeting at the Georgia World Congress Center in Atlanta in December. The following reports provide summary coverage of meeting highlights,primarily focusing upon notable research breakthroughs relatingto hematological malignancies.
Advertisement
Advertisement
Trending on HCPLive
1
CT Air Trapping Metric May Predict Post-BLVR Pneumothorax Risk
2
Diabetes Dialogue: The International Diabetes Federation and Care Access in India, With Amit Gupta, MBBS, DNB
3
Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment
4
Saroglitazar Targets Bile Acid Dysregulation, Inflammation in PBC, With Raj Vuppalanchi, MD
5